Overview

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2004-10-01

Target enrollment:

Participant gender:

Summary

To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).

Phase:

Phase 4

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Capecitabine